Anti-Human sVCAM-1 / CD106 ELI-PAIR Kit Antibody, Unconjugated from Cell Sciences
Mouse Anti-HNF-1 Monoclonal Antibody, Unconjugated, Clone 2 from BD Biosciences Pharmingen
Mouse Anti-GLP-1 Monoclonal Antibody, Unconjugated, Clone HYB 147-12 from Santa Cruz Biotechnology, Inc.
Baculovirus system service from Abgent
Biology Products:(Date:11/6/2009)...wire/ -- EUCODIS Bioscience, a company,developing,... for the,chemical industry announced today that it...dus, the leading biopharmaceutical company in Lati...Bioscience exclusive access - for the search,of en...ection of,psychrophilic bacteria strains and other...
(Date:11/6/2009)...re/ -- Calbiotech, Inc. announced today that it ha...h (SBIR) Phase I contract by the U.S. Army Medical... agreement, Calbiotech will develop analyte specif...us. ,, Dengue virus is a mosquito-born flavi...orces deployed to tropical areas of the world. Due...
(Date:11/6/2009)... Intarcia Therapeutics, Inc. delivered two present...us delivery of exenatide) program for the treatmen...Technology Meeting in San Francisco, CA: ,, (Lo...SFTU126LOGO ) ,, Continuous Subcutaneous Deli...se, HbA1c and Reduces Weight in a 28-day Phase 1b ...
(Date:11/5/2009)... Fuel economy ratings for the new 2010 model year...y.gov web site, which Oak Ridge National Laborato... of Energy and the U.S. Environmental Protection A...l economy list are hybrid electrics, led by the To...roves that hybrids have gone mainstream," said pro...
Breaking Biology Technology:EUCODIS Bioscience to Explore Novel Enzymatic Activities in Antarctic Bacteria Library From Bio Sidus 2Calbiotech Awarded U.S. Army Phase I SBIR Research Contract to Develop Analyte Specific Reagents for the Diagnosis of Dengue Fever Virus 2Intarcia Therapeutics, Inc. Presents Positive Results from Two Studies of ITCA 650 for the Treatment of Type 2 Diabetes at the Ninth Annual Diabetes Technology Meeting 2Intarcia Therapeutics, Inc. Presents Positive Results from Two Studies of ITCA 650 for the Treatment of Type 2 Diabetes at the Ninth Annual Diabetes Technology Meeting 3Intarcia Therapeutics, Inc. Presents Positive Results from Two Studies of ITCA 650 for the Treatment of Type 2 Diabetes at the Ninth Annual Diabetes Technology Meeting 4Intarcia Therapeutics, Inc. Presents Positive Results from Two Studies of ITCA 650 for the Treatment of Type 2 Diabetes at the Ninth Annual Diabetes Technology Meeting 5November 2009 story tips from the US Department of Energy's Oak Ridge National Laboratory 2November 2009 story tips from the US Department of Energy's Oak Ridge National Laboratory 3